Terms: = Thyroid cancer AND ELN, ENSG00000049540, 2006, WS, WBS, SVAS, FLJ43523, FLJ38671 AND Clinical Outcome
10 results:
1. Evaluation of Diagnostic Value of SPECT/CT Imaging in Post-radioiodine Therapy in thyroid cancer.
Al Hatmi A; Jain A; Mittal AK; Hussain S
Sultan Qaboos Univ Med J; 2022 Feb; 22(1):74-81. PubMed ID: 35299812
[TBL] [Abstract] [Full Text] [Related]
2. Combined immunosuppression and radiotherapy in thyroid eye disease (CIRTED): a multicentre, 2 × 2 factorial, double-blind, randomised controlled trial.
Rajendram R; Taylor PN; Wilson VJ; Harris N; Morris OC; Tomlinson M; Yarrow S; Garrott H; Herbert HM; Dick AD; Cook A; Gattamaneni R; Jain R; Olver J; Hurel SJ; Bremner F; Drummond SR; Kemp E; Ritchie DM; Rumsey N; Morris D; Lane C; Palaniappan N; Li C; Pell J; Hills R; Ezra DG; Potts MJ; Jackson S; Rose GE; Plowman N; Bunce C; Uddin JM; Lee RWJ; Dayan CM
Lancet Diabetes Endocrinol; 2018 Apr; 6(4):299-309. PubMed ID: 29396245
[TBL] [Abstract] [Full Text] [Related]
3. Low-dose radioiodine ablation in differentiated thyroid cancer with macroscopic extrathyroidal extension and low level of preablative-stimulated thyroglobulin.
Zhang Y; Liang J; Yang X; Yang K; Lin Y
Nucl Med Commun; 2015 Jun; 36(6):553-9. PubMed ID: 25793928
[TBL] [Abstract] [Full Text] [Related]
4. Current status of PET imaging of differentiated thyroid cancer with second generation radiopharmaceuticals.
Lauri C; Di Traglia S; Galli F; Pizzichini P; Signore A
Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):105-15. PubMed ID: 25737424
[TBL] [Abstract] [Full Text] [Related]
5. Comparison of presentation and clinical outcome between children and young adults with differentiated thyroid cancer.
Wang JT; Huang R; Kuang AR
Asian Pac J Cancer Prev; 2014; 15(17):7271-5. PubMed ID: 25227827
[TBL] [Abstract] [Full Text] [Related]
6. clinical outcome in differentiated thyroid carcinoma and microcarcinoma.
Lupoli R; Cacciapuoti M; Tortora A; Barba L; Verde N; Romano F; Vastarella M; Fonderico F; Masone S; Milone M; Lupoli G; Lupoli GA
Int J Surg; 2014; 12 Suppl 1():S148-51. PubMed ID: 24859408
[TBL] [Abstract] [Full Text] [Related]
7. Long-term follow-up of patients with differentiated thyroid cancer who had negative 131I whole-body scan at first evaluation after treatment.
Caminha LS; Momesso DP; Vaisman F; Corbo R; Vaisman M
Clin Nucl Med; 2013 Oct; 38(10):765-9. PubMed ID: 23917784
[TBL] [Abstract] [Full Text] [Related]
8. [Assessment of diagnostic criteria for FDG-PET cancer screening program according to the interpretation of FDG-PET and combined examination].
Minamimoto R; Senda M; Jinnouchi S; Yoshida T; Nakashima R; Nishizawa S; Terauchi T; Kawamoto M; Inoue T
Kaku Igaku; 2009 Jun; 46(2):73-93. PubMed ID: 19637819
[TBL] [Abstract] [Full Text] [Related]
9. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract] [Full Text] [Related]
10. outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.
van Tol KM; Jager PL; de Vries EG; Piers DA; Boezen HM; Sluiter WJ; Dullaart RP; Links TP
Eur J Endocrinol; 2003 Jun; 148(6):589-96. PubMed ID: 12773129
[TBL] [Abstract] [Full Text] [Related]
